Larue, R. T. H. M., Van De Voorde, L., Berbée, M., van Elmpt, W. J. C., Dubois, L. J., Panth, K. M., . . . Lambin, P. (2016). A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. BMC Cancer.
Citación estilo ChicagoLarue, Ruben T. H. M., et al. "A Phase 1 ‘window-of-opportunity’ Trial Testing Evofosfamide (TH-302), a Tumour-selective Hypoxia-activated Cytotoxic Prodrug, With Preoperative Chemoradiotherapy in Oesophageal Adenocarcinoma Patients." BMC Cancer 2016.
Cita MLALarue, Ruben T. H. M., et al. "A Phase 1 ‘window-of-opportunity’ Trial Testing Evofosfamide (TH-302), a Tumour-selective Hypoxia-activated Cytotoxic Prodrug, With Preoperative Chemoradiotherapy in Oesophageal Adenocarcinoma Patients." BMC Cancer 2016.